Epigral Limited Stock Price Today (NSE: EPIGRAL)

Epigral Limited

1084.008.20 (0.75%)
Market Closed

Fundamental Score

...

Epigral Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Epigral Limited share price today is 1084.00, down 0.75% on NSE/BSE as of 16 September 2026. Epigral Limited (EPIGRAL) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of 4.68K (Cr). The 52-week high for EPIGRAL share price is 1808.80 and the 52-week low is 807.00. At a P/E ratio of 17.26x, EPIGRAL is currently trading below its industry average P/E of 31.95x. The company has a Return on Equity (ROE) of 16.09% and a debt-to-equity ratio of 0.25.

Epigral Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
1264.80
Low
1054.60
Volume
76.6K
Change
+5.61%

Epigral Limited share price chart: 5.61% return over the past month. 52-week high ₹1808.80, 52-week low ₹807.00.

Epigral Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
1092.201092.201054.101084.0021.63K (Cr)
1134.801136.601076.701092.2049.51K (Cr)
1155.901155.901117.001131.1022.43K (Cr)
1166.101175.001140.001149.8036.00K (Cr)
1185.801189.801160.001163.9032.83K (Cr)
1215.001215.001172.401189.8030.44K (Cr)
1228.001231.801176.101179.8050.80K (Cr)
1230.001254.801214.501219.7048.19K (Cr)
1236.801254.801221.201236.7039.18K (Cr)
1235.001240.801206.201230.6035.16K (Cr)

Epigral Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
1208.601254.801054.101084.00-10.31%
1095.001264.801054.601203.30+9.89%
1085.001214.00969.001088.70+0.34%
1178.001190.001051.901084.10-7.97%
1225.001400.001146.241155.90-5.64%
822.001236.95818.801215.65+47.89%
850.00909.00807.00810.45-4.65%
975.701073.50885.00891.80-8.60%
1232.701270.30996.001043.10-15.38%
1518.501535.201212.801220.10-19.65%
1690.001709.001398.001511.70-10.55%
1691.101771.001661.001689.70-0.08%

Returns & Performance

Average

Return on Equity (ROE)

16.09%

Profit generated per ₹1 of shareholder equity

Average

Return on Capital (ROCE)

15.17%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

27.84%

Average operating profit margin over 5 years

Dividend Yield

0.48%

Annual dividend as % of current share price

Epigral Limited Valuation Check

Excellent

Price to Earnings (P/E)

17.26x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.95x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

68.83%

% shares held by company founders/management

Poor

FII Holding

1.54%

% shares held by foreign institutional investors

Poor

DII Holding

4.90%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-37.93%

Net profit growth vs same quarter last year

Average

Revenue Growth (Quarterly YoY)

16.29%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

24.99%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

25.29%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

26.46%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.25x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

5.75x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

323.67 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Epigral Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of EPIGRAL across key market metrics for learning purposes.

Positive Indicators

14 factors identified

Strong Return on Equity (16.09%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (15.17%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (27.84%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 17.26 vs Industry: 31.95)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Revenue Growth (16.29%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (24.99% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (25.29% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (26.46% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.25)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (5.75x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 1.57)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹323.67 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (68.83%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Profit Decline Concern (-37.93%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Limited Institutional Interest (FII+DII: 6.44%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

Epigral Limited vs Specialty Chemicals Peers

Peer Comparison - Specialty Chemicals

Compare Epigral Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
69.4/100
1084
₹4676.38
17.3
Average
16.09%
Good
15.17%
Good
0.3
Excellent
26.46%
Excellent
24.99%
Excellent
0.48%
65.3/100
1574
₹160150.83
60.5
Average
23.79%
Excellent
29.92%
Excellent
0.0
Excellent
16.70%
Excellent
14.89%
Good
0.73%
42.9/100
4684
₹51519.60
84.1
Average
7.65%
Poor
10.87%
Average
0.3
Excellent
36.34%
Excellent
13.52%
Good
0.07%
62.7/100
8858
₹45441.54
57.5
Average
20.11%
Excellent
21.48%
Excellent
0.3
Excellent
20.84%
Excellent
22.95%
Excellent
0.20%
32.8/100
1665
₹22710.60
29.0
Average
9.81%
Poor
11.31%
Average
0.3
Excellent
-6.63%
Poor
12.59%
Good
0.44%
36.3/100
1633
₹21676.01
91.9
Average
9.38%
Poor
12.78%
Average
0.2
Excellent
0.00%
58.2/100
6282
₹18494.21
23.3
Average
11.47%
Average
14.24%
Average
0.0
Excellent
54.89%
Excellent
10.95%
Good
0.49%
38.7/100
498
₹18061.64
34.0
Average
7.25%
Poor
8.86%
Poor
0.8
Good
-4.35%
Poor
12.96%
Good
0.20%
52.2/100
3802
₹16458.86
25.6
Average
0.00%
Poor
14.04%
Average
0.0
Excellent
7.67%
Good
9.35%
Good
0.68%
62.09999999999999/100
5145
₹15774.57
36.0
Average
16.82%
Good
21.91%
Excellent
0.0
Excellent
28.23%
Excellent
15.86%
Excellent
0.21%
33.3/100
1225
₹13940.69
79.6
Average
5.50%
Poor
9.10%
Poor
0.5
Good
19.33%
Excellent
23.88%
Excellent
0.06%

Epigral Limited PE Ratio History

Historical price-to-earnings ratio for EPIGRAL — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202584.68₹1220.1014.4x
FY 202447.14₹1896.2040.2x
FY 202385.03₹977.0511.5x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Epigral Limited Dividend History

Annual cash dividends paid by EPIGRAL — dividend yield 0.48%

Financial YearDividends Paid (₹ Cr)
FY 202541.86 Cr
FY 202425.12 Cr
FY 202324.22 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Epigral Limited Quarterly Performance

Latest quarterly metrics for EPIGRAL — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

16.29%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-37.93%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

24.99%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

26.46%

Compounded annual net profit growth over 5 years

Epigral Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for EPIGRAL — calculated from daily price history

64RSI 14
Neutral — RSI 64

Momentum is balanced — neither overbought nor oversold.

SMA 50
1118
▼ Price below SMA 50 — Short-term bearish
SMA 200
1141
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
70K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Epigral Limited Financial Statements

Annual income statement, balance sheet and cash flow for Epigral Limited (EPIGRAL) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Epigral Limited

Loading latest quarterly results...

About EPIGRAL (Epigral Limited)

Epigral Ltd is a dynamic force in the specialty chemicals arena, carving a niche for itself through innovative manufacturing and a commitment to global reach. The company stands as... a vertically integrated entity, mastering the complexities of the chlor-alkali process to produce a diverse range of high-value derivatives. More than just a manufacturer, Epigral is a creator of essential building blocks for a multitude of industries, transforming raw materials into specialized compounds that fuel progress and enable advanced applications. Epigral's unwavering focus on quality, safety, and sustainability ensures that its products not only meet but exceed industry standards, establishing it as a trusted partner in a competitive market. At the heart of Epigral's operations lies a dedication to harnessing the power of chlorine and its derivatives. From the resilient chlorinated polyvinyl chloride (CPVC) resins and compounds that fortify infrastructure to the reactive epichlorohydrin that forms the basis of countless epoxy resins, Epigral's product portfolio is both diverse and strategically focused. The company also demonstrates expertise in the chloromethanes value chain and produces hydrogen peroxide, caustic soda and potash, chlorine and hydrogen, offering a comprehensive suite of chemicals indispensable to various industrial processes. Epigral's commitment to self-sufficiency is evident in its captive power plant (CPP) and chlorotoluene value chain and its strategic investments in renewable energy through wind-solar hybrid power plants. Epigral's impact resonates across a broad spectrum of applications. Its CPVC resins and compounds are pivotal in the manufacturing of robust CPVC pipes and fittings, ensuring reliable fluid transport. Furthermore, its chemical solutions find application in diverse sectors, including windmills, construction, paints, and pharmaceuticals, solidifying Epigral's position as a key supplier in the global market. Through continuous innovation and a customer-centric approach, Epigral is dedicated to providing solutions that drive efficiency, enhance performance, and contribute to a more sustainable future for its partners and the planet.

Company Details

Symbol:EPIGRAL
Industry:Specialty Chemicals
Sector:Specialty Chemicals

Key Leadership

Mr. Maulik Jayantibhai Patel
Chairman & MD
Mr. Kaushal Ashisbhai Soparkar
CEO & Executive Director
Mr. Gaurang Ghanshyam Trivedi
Company Secretary & Compliance Officer

EPIGRAL Share Price: Frequently Asked Questions

What is the current share price of Epigral Limited?

Epigral Limited (EPIGRAL) trades at ₹1084.00 on NSE and BSE. Market cap ₹4.68K (Cr). Educational data only.

What is the P/E ratio of Epigral Limited?

Epigral Limited has a P/E of 17.26x vs industry average 31.95x.

What is the Bull Run score for Epigral Limited?

Epigral Limited has a Bull Run score of 69.4/100 based on 25+ financial parameters.

Does Epigral Limited pay dividends?

Epigral Limited has a dividend yield of 0.48%. Past dividends don't guarantee future payments.

What is the ROE of Epigral Limited?

Epigral Limited has ROE of 16.09%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Epigral Limited?

Epigral Limited has debt-to-equity of 0.25.

Is Epigral Limited a good investment?

Bull Run gives Epigral Limited a score of 69.4/100. This is not investment advice — consult a SEBI-registered advisor.